A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer

Trial Profile

A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Goserelin (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Luye Pharma Group
  • Most Recent Events

    • 22 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 06 Oct 2016 New trial record
    • 02 Sep 2016 This trial has been approved by United States Food and Drug Administration (USFDA), as reported by a Luye Pharma Group media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top